{"id":53799,"date":"2023-02-09T18:02:03","date_gmt":"2023-02-09T17:02:03","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/nexus-pharmaceuticals-inc-receives-fda-approval-for-tirofiban-hydrochloride-injection\/"},"modified":"2023-02-09T18:02:03","modified_gmt":"2023-02-09T17:02:03","slug":"nexus-pharmaceuticals-inc-receives-fda-approval-for-tirofiban-hydrochloride-injection","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/nexus-pharmaceuticals-inc-receives-fda-approval-for-tirofiban-hydrochloride-injection\/","title":{"rendered":"Nexus Pharmaceuticals Inc. Receives FDA Approval for Tirofiban Hydrochloride Injection"},"content":{"rendered":"
\n

LINCOLNSHIRE, Ill.–(BUSINESS WIRE)–#ANDA<\/a>–Nexus Pharmaceuticals Inc. announced that it has received US Food and Drug Administration (FDA) approval for Tirofiban Hydrochloride Injection in 5mg\/100mL single-dose IV-bags. Tentative approval has been granted for concentrations of 12.5mg\/250mL single-dose IV-bags. It is an AP-rated generic to AGGRASTAT\u00ae<\/sup>\u00a5.\n<\/p>\n

<\/a><\/p>\n

\n\u201cWe look forward to expanding our product range in the cardiovascular and IV solution space,\u201d said Usman Ahmed, President and CEO. \u201cBeing granted this approval is a milestone for us, but also for patients who want more transparency in the healthcare they receive. We eagerly anticipate bringing it to market in the coming months.\u201d\n<\/p>\n

\nNexus Pharmaceuticals\u2019 Tirofiban Hydrochloride for Injection will be available in cartons of sole single-dose IV bags.\n<\/p>\n

\nAbout Tirofiban Hydrochloride for Injection<\/b>\n<\/p>\n

\nTirofiban Hydrochloride for Injection is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia\/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome.\n<\/p>\n

\nFor prescribing information, please see the following link<\/a>.\n<\/p>\n

\nAbout Nexus Pharmaceuticals Inc.<\/b>\n<\/p>\n

\nNexus Pharmaceuticals Inc., a US-based healthcare company and certified diverse supplier, specializes in innovative processes to make difficult-to-manufacture specialty and generic drugs that are easier to use, less labor-intensive, and more streamlined in practice. Nexus ensures that its high-quality FDA-approved drugs fulfill a critical unmet medical need and delivers dependable life-saving treatment options when and where they\u2019re needed most. For more information about Nexus Pharmaceuticals and its state-of-the-art manufacturing facility in Wisconsin, visit https:\/\/www.nexuspharma.net\/project-tomorrow\/<\/a>.\n<\/p>\n

\n\u00a5AGGRASTAT\u00ae<\/sup> is a registered trademark of Medicure Inc.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nDeana Mndrucic
\n
dmndrucic@nexuspharma.net<\/a>
847-996-3790\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

LINCOLNSHIRE, Ill.–(BUSINESS WIRE)–#ANDA–Nexus Pharmaceuticals Inc. announced that it has received US Food and Drug Administration (FDA) approval for Tirofiban Hydrochloride Injection in 5mg\/100mL single-dose IV-bags. Tentative approval has been granted for concentrations of 12.5mg\/250mL single-dose IV-bags. It is an AP-rated generic to AGGRASTAT\u00ae\u00a5. \u201cWe look forward to expanding our product range in the cardiovascular and … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-53799","6":"format-standard","7":"category-industry"},"yoast_head":"\nNexus Pharmaceuticals Inc. Receives FDA Approval for Tirofiban Hydrochloride Injection - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/nexus-pharmaceuticals-inc-receives-fda-approval-for-tirofiban-hydrochloride-injection\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nexus Pharmaceuticals Inc. Receives FDA Approval for Tirofiban Hydrochloride Injection - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"LINCOLNSHIRE, Ill.–(BUSINESS WIRE)–#ANDA–Nexus Pharmaceuticals Inc. announced that it has received US Food and Drug Administration (FDA) approval for Tirofiban Hydrochloride Injection in 5mg\/100mL single-dose IV-bags. Tentative approval has been granted for concentrations of 12.5mg\/250mL single-dose IV-bags. It is an AP-rated generic to AGGRASTAT\u00ae\u00a5. \u201cWe look forward to expanding our product range in the cardiovascular and ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/nexus-pharmaceuticals-inc-receives-fda-approval-for-tirofiban-hydrochloride-injection\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-09T17:02:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230209005576\/en\/834934\/21\/NexusLogoFinal10.2.15_transparent.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nexus-pharmaceuticals-inc-receives-fda-approval-for-tirofiban-hydrochloride-injection\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nexus-pharmaceuticals-inc-receives-fda-approval-for-tirofiban-hydrochloride-injection\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Nexus Pharmaceuticals Inc. Receives FDA Approval for Tirofiban Hydrochloride Injection\",\"datePublished\":\"2023-02-09T17:02:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nexus-pharmaceuticals-inc-receives-fda-approval-for-tirofiban-hydrochloride-injection\\\/\"},\"wordCount\":275,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nexus-pharmaceuticals-inc-receives-fda-approval-for-tirofiban-hydrochloride-injection\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230209005576\\\/en\\\/834934\\\/21\\\/NexusLogoFinal10.2.15_transparent.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nexus-pharmaceuticals-inc-receives-fda-approval-for-tirofiban-hydrochloride-injection\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nexus-pharmaceuticals-inc-receives-fda-approval-for-tirofiban-hydrochloride-injection\\\/\",\"name\":\"Nexus Pharmaceuticals Inc. Receives FDA Approval for Tirofiban Hydrochloride Injection - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nexus-pharmaceuticals-inc-receives-fda-approval-for-tirofiban-hydrochloride-injection\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nexus-pharmaceuticals-inc-receives-fda-approval-for-tirofiban-hydrochloride-injection\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230209005576\\\/en\\\/834934\\\/21\\\/NexusLogoFinal10.2.15_transparent.jpg\",\"datePublished\":\"2023-02-09T17:02:03+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nexus-pharmaceuticals-inc-receives-fda-approval-for-tirofiban-hydrochloride-injection\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nexus-pharmaceuticals-inc-receives-fda-approval-for-tirofiban-hydrochloride-injection\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nexus-pharmaceuticals-inc-receives-fda-approval-for-tirofiban-hydrochloride-injection\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230209005576\\\/en\\\/834934\\\/21\\\/NexusLogoFinal10.2.15_transparent.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230209005576\\\/en\\\/834934\\\/21\\\/NexusLogoFinal10.2.15_transparent.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nexus-pharmaceuticals-inc-receives-fda-approval-for-tirofiban-hydrochloride-injection\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nexus Pharmaceuticals Inc. Receives FDA Approval for Tirofiban Hydrochloride Injection\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nexus Pharmaceuticals Inc. Receives FDA Approval for Tirofiban Hydrochloride Injection - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/nexus-pharmaceuticals-inc-receives-fda-approval-for-tirofiban-hydrochloride-injection\/","og_locale":"en_US","og_type":"article","og_title":"Nexus Pharmaceuticals Inc. Receives FDA Approval for Tirofiban Hydrochloride Injection - Pharma Trend","og_description":"LINCOLNSHIRE, Ill.–(BUSINESS WIRE)–#ANDA–Nexus Pharmaceuticals Inc. announced that it has received US Food and Drug Administration (FDA) approval for Tirofiban Hydrochloride Injection in 5mg\/100mL single-dose IV-bags. Tentative approval has been granted for concentrations of 12.5mg\/250mL single-dose IV-bags. It is an AP-rated generic to AGGRASTAT\u00ae\u00a5. \u201cWe look forward to expanding our product range in the cardiovascular and ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/nexus-pharmaceuticals-inc-receives-fda-approval-for-tirofiban-hydrochloride-injection\/","og_site_name":"Pharma Trend","article_published_time":"2023-02-09T17:02:03+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230209005576\/en\/834934\/21\/NexusLogoFinal10.2.15_transparent.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/nexus-pharmaceuticals-inc-receives-fda-approval-for-tirofiban-hydrochloride-injection\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/nexus-pharmaceuticals-inc-receives-fda-approval-for-tirofiban-hydrochloride-injection\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Nexus Pharmaceuticals Inc. Receives FDA Approval for Tirofiban Hydrochloride Injection","datePublished":"2023-02-09T17:02:03+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/nexus-pharmaceuticals-inc-receives-fda-approval-for-tirofiban-hydrochloride-injection\/"},"wordCount":275,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/nexus-pharmaceuticals-inc-receives-fda-approval-for-tirofiban-hydrochloride-injection\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230209005576\/en\/834934\/21\/NexusLogoFinal10.2.15_transparent.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/nexus-pharmaceuticals-inc-receives-fda-approval-for-tirofiban-hydrochloride-injection\/","url":"https:\/\/pharma-trend.com\/en\/nexus-pharmaceuticals-inc-receives-fda-approval-for-tirofiban-hydrochloride-injection\/","name":"Nexus Pharmaceuticals Inc. Receives FDA Approval for Tirofiban Hydrochloride Injection - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/nexus-pharmaceuticals-inc-receives-fda-approval-for-tirofiban-hydrochloride-injection\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/nexus-pharmaceuticals-inc-receives-fda-approval-for-tirofiban-hydrochloride-injection\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230209005576\/en\/834934\/21\/NexusLogoFinal10.2.15_transparent.jpg","datePublished":"2023-02-09T17:02:03+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/nexus-pharmaceuticals-inc-receives-fda-approval-for-tirofiban-hydrochloride-injection\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/nexus-pharmaceuticals-inc-receives-fda-approval-for-tirofiban-hydrochloride-injection\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/nexus-pharmaceuticals-inc-receives-fda-approval-for-tirofiban-hydrochloride-injection\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230209005576\/en\/834934\/21\/NexusLogoFinal10.2.15_transparent.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230209005576\/en\/834934\/21\/NexusLogoFinal10.2.15_transparent.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/nexus-pharmaceuticals-inc-receives-fda-approval-for-tirofiban-hydrochloride-injection\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Nexus Pharmaceuticals Inc. Receives FDA Approval for Tirofiban Hydrochloride Injection"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53799","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=53799"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53799\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=53799"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=53799"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=53799"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}